Valeant Pharmaceuticals International Inc. (NYSE:VRX)’s share price traded up 3.4% during mid-day trading on Thursday . The stock traded as high as $23.07 and last traded at $22.35, with a volume of 34,726,015 shares changing hands. The stock had previously closed at $21.62.

Several equities analysts have recently issued reports on the stock. Rodman & Renshaw restated a “buy” rating and set a $105.00 price objective on shares of Valeant Pharmaceuticals International in a report on Tuesday, April 26th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Valeant Pharmaceuticals International in a research report on Tuesday, April 26th. Canaccord Genuity reiterated a “hold” rating and issued a $40.00 target price on shares of Valeant Pharmaceuticals International in a research report on Wednesday, April 27th. Guggenheim reiterated a “buy” rating and issued a $55.00 target price on shares of Valeant Pharmaceuticals International in a research report on Monday, April 25th. Finally, Wells Fargo & Co. reiterated a “sell” rating on shares of Valeant Pharmaceuticals International in a research report on Monday, April 25th. Seven research analysts have rated the stock with a sell rating, fifteen have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $66.43.

The stock has a 50 day moving average price of $23.75 and a 200 day moving average price of $50.43. The firm’s market capitalization is $7.90 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last issued its earnings results on Tuesday, June 7th. The specialty pharmaceutical company reported $1.27 earnings per share for the quarter, missing analysts’ consensus estimates of $1.37 by $0.10. The business had revenue of $2.37 billion for the quarter, compared to analysts’ expectations of $2.34 billion. Valeant Pharmaceuticals International’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.36 EPS. On average, analysts predict that Valeant Pharmaceuticals International Inc. will post $6.63 earnings per share for the current fiscal year.

In related news, CEO Joseph C. Papa bought 202,000 shares of the business’s stock in a transaction on Friday, June 10th. The shares were purchased at an average price of $24.48 per share, for a total transaction of $4,944,960.00. Following the completion of the transaction, the chief executive officer now directly owns 2,442,199 shares of the company’s stock, valued at approximately $59,785,031.52. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Several institutional investors have added to or reduced their stakes in VRX. Dimensional Fund Advisors LP increased its position in Valeant Pharmaceuticals International by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 79,777 shares of the specialty pharmaceutical company’s stock valued at $8,110,000 after buying an additional 2,500 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in Valeant Pharmaceuticals International by 253.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 284,308 shares of the specialty pharmaceutical company’s stock valued at $28,900,000 after buying an additional 203,760 shares during the last quarter. I.G. Investment Management LTD. increased its position in Valeant Pharmaceuticals International by 31.0% in the fourth quarter. I.G. Investment Management LTD. now owns 1,328,610 shares of the specialty pharmaceutical company’s stock valued at $135,033,000 after buying an additional 314,616 shares during the last quarter. Diamond Hill Capital Management Inc. increased its position in Valeant Pharmaceuticals International by 77.8% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 301,374 shares of the specialty pharmaceutical company’s stock valued at $30,635,000 after buying an additional 131,832 shares during the last quarter. Finally, Marshall Wace LLP increased its position in Valeant Pharmaceuticals International by 76.6% in the fourth quarter. Marshall Wace LLP now owns 65,386 shares of the specialty pharmaceutical company’s stock valued at $6,647,000 after buying an additional 28,365 shares during the last quarter.

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.